Valproate-induced Hepatic Steatogenesis in Rats
Overview
Authors
Affiliations
The administration of high-dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague-Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low-dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed-function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental; model may permit exploration of factors that enhance or inhibit VPA-induced hepatic injury.
Naderi M, Ahangar N, Badakhshan F, Ghasemi M, Shaki F Anat Cell Biol. 2021; 54(3):387-394.
PMID: 34588319 PMC: 8493015. DOI: 10.5115/acb.20.280.
Poolchanuan P, Unagul P, Thongnest S, Wiyakrutta S, Ngamrojanavanich N, Mahidol C Sci Rep. 2020; 10(1):9300.
PMID: 32518288 PMC: 7283484. DOI: 10.1038/s41598-020-66251-y.
Valproate-induced Drug Rash Eosinophilia with Systemic Symptoms Syndrome: An Unknown Hepatotoxicity.
Gupta T Euroasian J Hepatogastroenterol. 2020; 9(2):102-103.
PMID: 32117699 PMC: 7047308. DOI: 10.5005/jp-journals-10018-1298.
Al-Amoudi W Saudi J Biol Sci. 2017; 24(4):915-924.
PMID: 28490965 PMC: 5415150. DOI: 10.1016/j.sjbs.2016.10.021.
Valproic acid and nonalcoholic fatty liver disease: A possible association?.
Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A World J Hepatol. 2015; 7(9):1251-7.
PMID: 26019740 PMC: 4438499. DOI: 10.4254/wjh.v7.i9.1251.